基于HbA1c的糖尿病筛查对COVID-19患者血糖异常患病率及影响的意义
在2020年11月1日至2021年3月8日期间,对非重症监护病房的COVID-19住院患者进行系统筛查,比较基于糖化血红蛋白A1c(HbA1c)、随机血糖和已知病史的筛查策略(ABC)与仅基于随机血糖和已知病史的策略(BC)对血糖异常检出率及COVID-19严重程度风险估计的影响。结果显示,ABC策略下糖尿病和糖尿病前期患病率分别为38.2%和37.5%,且血糖异常与更严重的COVID-19相关;BC策略未能识别大部分糖尿病前期和部分糖尿病,并遗漏了血糖异常与COVID-19严重程度的关联。
要点
- 在ABC筛查策略下,糖尿病和糖尿病前期的患病率分别为38.2%和37.5%。
- 糖尿病与更严重的COVID-19风险增加相关(aOR 2.27和3.26)。
- 糖尿病前期患者也更常出现更严重的COVID-19(aOR 1.76和2.41)。
核心结论
- 大流行条件可能妨碍血糖异常检出率,进而影响对个体患者COVID-19严重程度风险的认知。
- 包含HbA1c的系统性糖尿病筛查可减少既往未知或新发血糖异常的漏诊,并提高风险估计质量及高危患者获得糖尿病特异性干预的机会。
研究设计与样本
- 研究为非重症监护病房的COVID-19住院患者,于2020年11月1日至2021年3月8日期间进行系统筛查,采用HbA1c、随机血糖和已知病史(ABC)与随机血糖和已知病史(BC)两种筛查策略进行分析。
- 共筛查并分析了601例入院患者中的578例(96.2%)。
主要发现
- 在ABC策略下,糖尿病和糖尿病前期的患病率分别为38.2%和37.5%。
- 糖尿病与更严重的COVID-19风险增加显著相关(调整比值比[aOR] [中度COVID-19]:2.27,95% CI 1.16-4.46;aOR [重度COVID-19]:3.26,95% CI 1.56-6.38)。
- 糖尿病前期患者也更常出现更严重的COVID-19(aOR [中度COVID-19]:1.76,95% CI 1.04-2.97;aOR [重度COVID-19]:2.41,95% CI 1.37-4.23)。
- BC筛查策略仅未能识别96%的糖尿病前期(206/217)和26.2%的糖尿病诊断(58/221),并遗漏了血糖异常与COVID-19严重程度的关联。
关键数值与推荐
- ABC策略下糖尿病患病率为38.2%,糖尿病前期患病率为37.5%。
- 糖尿病与中度COVID-19的aOR为2.27(95% CI 1.16-4.46),与重度COVID-19的aOR为3.26(95% CI 1.56-6.38)。
- 糖尿病前期与中度COVID-19的aOR为1.76(95% CI 1.04-2.97),与重度COVID-19的aOR为2.41(95% CI 1.37-4.23)。
- BC策略未能识别96%的糖尿病前期(206/217)和26.2%的糖尿病诊断(58/221)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In patients with severe acute respiratory syndrome coronavirus type 2 infection, diabetes is associated with poor COVID-19 prognosis. However, case detection strategy is divergent and reported prevalence varies from 5% to 35%. OBJECTIVE: We examined how far the choice of screening tools affects the detection rate of dysglycemia and in consequence the estimation of diagnosis-associated risk for moderate (mo) or severe (s) COVID-19. METHODS: Non-intensive care unit inpatients with COVID-19 were screened systematically at admission for diabetes (D) and prediabetes (PreD) by glycated hemoglobin A1c (HbA1c) (A), random blood glucose (B), and known history (C) from November 1, 2020 to March 8, 2021. Dysglycemia rate and effect on COVID-19 outcome were analyzed in 2 screening strategies (ABC vs BC). RESULTS: A total of 578 of 601 (96.2%) of admitted patients were screened and analyzed. In ABC, prevalence of D and PreD was 38.2% and 37.5%, respectively. D was significantly associated with an increased risk for more severe COVID-19 (adjusted odds ratio [aOR] [moCOVID-19]: 2.27, 95% CI, 1.16-4.46 and aOR [sCOVID-19]: 3.26, 95% CI, 1.56-6.38). Patients with PreD also presented more often with more severe COVID-19 than those with normoglycemia (aOR [moCOVID-19]: 1.76, 95% CI, 1.04-2.97 and aOR [sCOVID-19]: 2.41, 95% CI, 1.37-4.23). Screening with BC failed to identify only 96% of PreD (206/217) and 26.2% of D diagnosis (58/221) and missed associations of dysglycemia and COVID-19 severity. CONCLUSION: Pandemic conditions may hamper dysglycemia detection rate and in consequence the awareness of individual patient risk for COVID-19 severity. A systematic diabetes screening including HbA1c reduces underdiagnosis of previously unknown or new-onset dysglycemia, and enhances the quality of risk estimation and access of patients at risk to a diabetes-specific intervention.
引用
- Van Baal L, Reinold J, Benson S, et al. Implications of an HbA1c-based Diabetes Screening on Prevalence and Effect of Dysglycemia in Patients With COVID-19. J Clin Endocrinol Metab. 2023. PMID: 36221157. doi:10.1210/clinem/dgac590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。